Dr. Yael Mosse leads the Crazy 8 team that is studying and targeting the oncoprotein MCYN. 

For Dr. Mossé, enormous discoveries in science, new technologies and now, the collaboration made possible by the Crazy 8, have given her hope. 

“Hope is what gets us up in the morning. It’s what gives us the passion, the motivation, the resilience to keep going, even when we fall or when there are hard moments. That hope is what really gives us the strength and the courage to believe that we are going to make a big difference,” said Dr. Mossé.

As a physician-scientist at the Children’s Hospital of Philadelphia and member of the New Approaches to Neuroblastoma Therapy (NANT) Consortium, Dr. Mosse specializes in the study and treatment of neuroblastoma. In her lab, she’s studied the genetic drivers of neuroblastoma, led clinical trials investigating targeted drugs and made several notable discoveries. Dr. Mosse led a trial for criztonib, which led to the drug’s FDA approval for the treatment of heredity neuroblastoma  leading a and is leading a phase 3 trial for another ALK-inhibitor, lorlatinib.